xRead - Nonallergic Rhinitis (September 2025)

BAROODY ET AL

1447

J ALLERGY CLIN IMMUNOL PRACT VOLUME 12, NUMBER 6

66. Murdoch RD, Bareille P, Denyer J, Newlands A, Bentley J, Smart K, et al. TRPV1 inhibition does not prevent cold dry air e elicited symptoms in non allergic rhinitis. Int J Clin Pharmacol Ther 2014;52:267-76. 67. Zhang K, Pipaliya RM, Miglani A, Nguyen SA, Schlosser RJ. Systematic re view of surgical interventions for inferior turbinate hypertrophy. Am J Rhinol Allergy 2023;37:110-22. 68. Golding-Wood PH. Observations on petrosal and vidian neurectomy in chronic vasomotor rhinitis. J Laryngol Otol 1961;75:232-47. 69. Zhang H, Micomonaco DC, Dziegielewski PT, Sowerby LJ, Weis E, Wright ED. Endoscopic vidian neurectomy: a prospective case series. Int Forum Allergy Rhinol 2015;5:423-30. 70. Ma Y, Tan G, Zhao Z, Li W, Huang L, Liu G. Therapeutic effectiveness of endoscopic vidian neurectomy for the treatment of vasomotor rhinitis. Acta Otolaryngol 2014;134:260-7. 71. Chang MT, Song S, Hwang PH. Cryosurgical ablation for treatment of rhinitis: a prospective multicenter study. Laryngoscope 2020;130:1877-84. 72. Ehmer D, McDuf fi e CM, Scurry WC Jr, McIntyre JB, Mehendale NH, Willis JH, et al. Temperature-controlled radiofrequency neurolysis for the treatment of rhinitis. Am J Rhinol Allergy 2022;36:149-56. 73. Smith AM, Rezvani M, Bernstein JA. Is response to allergen immunotherapy a good phenotypic marker for differentiating between allergic rhinitis and mixed rhinitis? Allergy Asthma Proc 2011;32:49-54. 74. US Food and Drug Administration. Nonallergic Rhinitis: developing drug products for treatment guidance for industry: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Accessed March 27, 2024. https://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm 75. Urbach E. Vasomotor rhinitis: a proposed classi fi cation based on an analysis of of seventy-four cases. Arch Otolaryngol 1941;33:982-92. 76. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999;104:301-4. 77. Elsheikh MN, Badran HM. Dysautonomia rhinitis: associated otolaryngologic manifestations and characterization based on autonomic function tests. Acta Otolaryngol 2006;126:1206-12. 78. Allendes FJ, Diaz HS, Ortiz FC, Marcus NJ, Quintanilla R, Inestrosa NC, et al. Cardiovascular and autonomic dysfunction in long-COVID syndrome and the potential role of non-invasive therapeutic strategies on cardiovascular outcomes. Front Med (Lausanne) 2022;9:1095249. 79. Fedorowski A, Sutton R. Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome. Nat Rev Cardiol 2023;20:281-2. 80. Bellanti JA, Novak P, Faitelson Y, Bernstein JA, Castells MC. The long road of long COVID: speci fi c considerations for the Allergist/Immunologist. J Allergy Clin Immunol Pract 2023;11:3335-45. 81. Kwan AC, Ebinger JE, Wei J, Le CN, Oft JR, Zabner R, et al. Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccina tion and SARS-Cov-2 infection. Nat Cardiovasc Res 2022;1:1187-94. 82. Scheire S, Germonpre S, Van Tongelen I, Mehuys E, Crombez G, Gevaert P, et al. The indispensable nasal decongestant: patients ’ views and perspectives on nasal decongestant overuse. J Allergy Clin Immunol Pract 2023;11:602-609.e1. 83. Baroody FM, Brown D, Gavanescu L, DeTineo M, Naclerio RM. Oxy metazoline adds to the effectiveness of fl uticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2011;127:927-34. 84. Meltzer EO, Bernstein DI, Prenner BM, Berger WE, Shekar T, Teper AA. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term ef fi cacy and safety in seasonal allergic rhinitis. Am J Rhinol Allergy 2013;27:102-8. 85. Vaidyanathan S, Williamson P, Clearie K, Khan F, Lipworth B. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010;182:19-24. 86. Halderman A, Sindwani R. Surgical management of vasomotor rhinitis: a sys tematic review. Am J Rhinol Allergy 2015;29:128-34. 87. Kompelli AR, Janz TA, Rowan NR, Nguyen SA, Soler ZM. Cryotherapy for the treatment of chronic rhinitis: a qualitative systematic review. Am J Rhinol Al lergy 2018;32:491-501.

44. Singh U, Bernstein JA, Haar L, Luther K, Jones WK. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Am J Rhinol Allergy 2014;28:215-24. 45. Park JH, Lee TJ, Park MJ, Oh HN, Jo YM. Effects of air cleaners and school characteristics on classroom concentrations of particulate matter in 34 elemen tary schools in Korea. Build Environ 2020;167:106437. 46. Head K, Snidvongs K, Glew S, Scadding G, Schilder AG, Philpott C, et al. Saline irrigation for allergic rhinitis. Cochrane Database Syst Rev 2018;6: CD012597. 47. El Khoury P, Abou Hamad W, Khalaf MG, El Hadi C, Assily R, Rassi S, et al. Ipratropium bromide nasal spray in non-allergic rhinitis: a systematic review and meta-analysis. Laryngoscope 2023;133:3247-55. 48. Khoueir N, Khalaf MG, Assily R, Rassi S, Hamad WA. Intranasal antihista mines in the treatment of idiopathic non-allergic rhinitis: a systematic review and meta-analysis. Rhinology 2023;61:290-6. 49. Meltzer EO. The treatment of vasomotor rhinitis with intranasal corticosteroids. World Allergy Organ J 2009;2:166-79. 50. Borson DB. Roles of neutral endopeptidase in airways. Am J Physiol 1991;260: L212-25. 51. Sont JK, van Krieken JH, van Klink HC, Roldaan AC, Apap CR, Willems LN, et al. Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid- versus nonsteroid-treated patients with atopic asthma. Am J Respir Cell Mol Biol 1997;16:549-56. 52. Piedimonte G, McDonald DM, Nadel JA. Glucocorticoids inhibit neurogenic plasma extravasation and prevent virus-potentiated extravasation in the rat tra chea. J Clin Invest 1990;86:1409-15. 53. Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, et al. Long term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fl uticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract 2014;2: 179-85. 54. Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013;23:495-503. 55. Bernstein JA. Nonallergic rhinitis: therapeutic options. Curr Opin Allergy Clin Immunol 2013;13:410-6. 56. Fokkens W, Hellings P, Segboer C. Capsaicin for rhinitis. Curr Allergy Asthma Rep 2016;16:60. 57. Gevorgyan A, Segboer C, Gorissen R, van Drunen CM, Fokkens W. Capsaicin for non-allergic rhinitis. Cochrane Database Syst Rev 2015;7:CD010591. 58. Docherty RJ, Yeats JC, Bevan S, Boddeke HW. Inhibition of calcineurin in hibits the desensitization of capsaicin-evoked currents in cultured dorsal root ganglion neurones from adult rats. P fl ugers Arch 1996;431:828-37. 59. Rosenbaum T, Gordon-Shaag A, Munari M, Gordon SE. Ca2 þ /calmodulin modulates TRPV1 activation by capsaicin. J Gen Physiol 2004;123:53-62. 60. Schwarz S, Greffrath W, Busselberg D, Treede RD. Inactivation and tachy phylaxis of heat-evoked inward currents in nociceptive primary sensory neu rones of rats. J Physiol 2000;528:539-49. 61. Liu B, Zhang C, Qin F. Functional recovery from desensitization of vanilloid receptor TRPV1 requires resynthesis of phosphatidylinositol 4,5-bisphosphate. J Neurosci 2005;25:4835-43. 62. Van Gerven L, Alpizar YA, Steelant B, Callebaut I, Kortekaas Krohn I, Wouters M, et al. Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment. J Allergy Clin Immunol 2017;140:437-446.e2. 63. Bernstein JA, Davis BP, Picard JK, Cooper JP, Zheng S, Levin LS. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a signi fi cant component of nonallergic rhinitis. Ann Allergy Asthma Immunol 2011;107:171-8. 64. Singh U, Bernstein JA. Intranasal capsaicin in management of nonallergic (vasomotor) rhinitis. Prog Drug Res 2014;68:147-70. 65. Van Gerven L, Steelant B, Cools L, Callebaut I, Backaert W, de Hoon J, et al. Low-dose capsaicin (0.01 mM) nasal spray is equally effective as the current standard treatment for idiopathic rhinitis: a randomized, double-blind, placebo controlled trial. J Allergy Clin Immunol 2021;147:397-400.e4.